Literature DB >> 31016559

In vitro activation and maturation of human mononuclear phagocytes by stimulation with liposomes coated with a neoglycolipid containing α1-3, α1-6-mannotriose.

Yuko Matsuoka1, Yoko Kawauchi1, Kiyotaka Kawauchi2, Akari Takiyama1, Shohei Kojima1, Yasuhiro Kuroda1, Naoya Kojima3.   

Abstract

In this study, we assessed the potential of liposomes coated with a neoglycolipid containing α1-3,α1-6-mannotriose residues (Man3-DPPE; Manα1-6(Manα1-3)Manitol-DPPE) for in vitro activation and maturation of human mononuclear phagocytes. In response to treatment with Man3-DPPE-coated liposomes (Man3-OMLs), PMA-stimulated human THP-1 cells showed enhanced expression of CD40, CD80 and HLA-DR and secreted significant levels of IL-12p40. Among various linkages of Man2-DPPE-coated liposomes, only liposomes coated with Manα1-6Manitol-DPPE (α1-6Man2-DPPE) induced these cellular responses similarly to Man3-OML treatment. Liposomes coated with Manα1-6(Manα1-3)Manα1-6(Manα1-3)Manitol-DPPE (Man5-DPPE) failed to activate the cells. These results suggest that an unsubstituted α1-6Man branch bound to a mannitol unit at the reducing end in Man3-DPPE is required for in vitro activation of human mononuclear phagocytes. Man3-OML-induced IL-12p40 production was not inhibited by BAY11-7082, an inhibitor of the MyD88-dependent signaling network, suggesting that TLRs are not involved in activation of human mononuclear phagocytes by Man3-OMLs. Stimulation of inflammatory monocytes or monocyte-derived dendritic cells (moDCs) with Man3-OMLs also induced enhanced expression of co-stimulatory molecules, HLA-DR, and CCR7, and IL-12p40 production from both types of cells. In response to Man3-OML treatment, moDCs but not inflammatory monocytes produced bioactive IL-12p70, which was enhanced by CD40 ligation. Thus, Man3-OMLs can activate naïve human mononuclear phagocytes and lead human moDCs to a fully matured status in vitro to elicit CTLs and a Th1 response without addition of inflammatory cytokines or TLR agonists.

Entities:  

Keywords:  Liposome; Monocyte; Monocyte-derived dendritic cell; Oligomannose-containing neoglycolipid; THP-1

Mesh:

Substances:

Year:  2019        PMID: 31016559     DOI: 10.1007/s10719-019-09870-6

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  41 in total

Review 1.  Mechanisms of phagocytosis in macrophages.

Authors:  A Aderem; D M Underhill
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

2.  Th1-polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: the importance of maturation cocktails.

Authors:  Wim Jongmans; Dorien M Tiemessen; Iris J H van Vlodrop; Peter F A Mulders; Egbert Oosterwijk
Journal:  J Immunother       Date:  2005 Sep-Oct       Impact factor: 4.456

Review 3.  The dendritic cell system and its role in immunogenicity.

Authors:  R M Steinman
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

Review 4.  Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape.

Authors:  Abhishek D Garg; Pierre G Coulie; Benoit J Van den Eynde; Patrizia Agostinis
Journal:  Trends Immunol       Date:  2017-06-10       Impact factor: 16.687

5.  Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy.

Authors:  Yasushi Ikuta; Naoyuki Katayama; Lijie Wang; Toshiharu Okugawa; Yoshiyuki Takahashi; Michael Schmitt; Xiaogang Gu; Masato Watanabe; Kazunari Akiyoshi; Hideo Nakamura; Kagemasa Kuribayashi; Junzo Sunamoto; Hiroshi Shiku
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

6.  Intraperitoneal immunization with oligomannose-coated liposome-entrapped soluble leishmanial antigen induces antigen-specific T-helper type immune response in BALB/c mice through uptake by peritoneal macrophages.

Authors:  Y Shimizu; H Takagi; T Nakayama; K Yamakami; T Tadakuma; N Yokoyama; N Kojima
Journal:  Parasite Immunol       Date:  2007-05       Impact factor: 2.280

7.  Cutting edge: secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes.

Authors:  H Saeki; A M Moore; M J Brown; S T Hwang
Journal:  J Immunol       Date:  1999-03-01       Impact factor: 5.422

8.  Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells.

Authors:  Yuzuru Ikehara; Nobumitsu Shiuchi; Sanae Kabata-Ikehara; Hayao Nakanishi; Naoaki Yokoyama; Hideaki Takagi; Toshi Nagata; Yukio Koide; Kiyotaka Kuzushima; Toshitada Takahashi; Kunio Tsujimura; Naoya Kojima
Journal:  Cancer Lett       Date:  2008-02-18       Impact factor: 8.679

9.  Oligomannose-coated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity.

Authors:  Naoya Kojima; Le Biao; Tomoko Nakayama; Mariko Ishii; Yuzuru Ikehara; Kunio Tsujimura
Journal:  J Control Release       Date:  2008-04-07       Impact factor: 9.776

Review 10.  Interleukin-12 and the regulation of innate resistance and adaptive immunity.

Authors:  Giorgio Trinchieri
Journal:  Nat Rev Immunol       Date:  2003-02       Impact factor: 53.106

View more
  2 in total

1.  Wall teichoic acid-dependent phagocytosis of intact cell walls of Lactiplantibacillus plantarum elicits IL-12 secretion from macrophages.

Authors:  Naoya Kojima; Shohei Kojima; Shin Hosokawa; Yoshiki Oda; Daisuke Zenke; Yuta Toura; Emi Onohara; Shin-Ichi Yokota; Masato Nagaoka; Yasuhiro Kuroda
Journal:  Front Microbiol       Date:  2022-08-09       Impact factor: 6.064

Review 2.  Various Tastes of Sugar: The Potential of Glycosylation in Targeting and Modulating Human Immunity via C-Type Lectin Receptors.

Authors:  Stefanie Busold; Noémi A Nagy; Sander W Tas; Ronald van Ree; Esther C de Jong; Teunis B H Geijtenbeek
Journal:  Front Immunol       Date:  2020-02-07       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.